<DOC>
	<DOCNO>NCT01129102</DOCNO>
	<brief_summary>The purpose study determine whether NPC-01 effective treatment dysmenorrhea .</brief_summary>
	<brief_title>Efficacy Safety Study NPC-01 Treat Dysmenorrhea</brief_title>
	<detailed_description>The main objective study confirm effectiveness safety profile NPC-01 comparison placebo treatment dysmenorrhea ( primary secondary dysmenorrhea ) . Additionally also investigate difference effectiveness NPC-01 comparison IKH-01 treatment secondary dysmenorrhea reference , IKH-01 already market . To achieve , close test procedure use study . After confirm statistical difference NPC-01 Placebo total dysmenorrhea , stratify analysis carry primary dysmenorrhea ( NPC-01 , Placebo ) , secondary dysmenorrhea ( NPC-01 , IKH-01 Placebo ) .</detailed_description>
	<mesh_term>Dysmenorrhea</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Norethindrone</mesh_term>
	<mesh_term>Norethindrone acetate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Anti-Inflammatory Agents , Non-Steroidal</mesh_term>
	<criteria>dysmenorrhea severe hepatopathy pregnant woman</criteria>
	<gender>Female</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>